We used two immunophenotypic scores (IPS) subtypes (IPS-PD-1/PD-L1/PD-L2_pos and IPS-CTLA-4_pos) as proxies for response to anti-PD-1/PD-L1 and anti-CTLA-4 treatment in patients with CESC. This evidence concerns the gene PDCD1LG2 and cervical squamous cell carcinoma.